NASDAQ:ENGN

enGene Q3 2026 Earnings Results & Report

enGene logo
$1.74 -0.03 (-1.42%)
As of 12:33 PM Eastern
This is a fair market value price provided by Massive. Learn more.

enGene missed analyst earnings expectations in its Q3 2026 results, released September 8, 2026. The company reported EPS of -$0.47 versus the -$0.4266 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call
7:00 AM ET

enGene EPS Results

Actual EPS
-$0.47
Consensus EPS
-$0.4266
Beat/Miss
Missed by -$0.0434
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

enGene Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

enGene's Q4 2026 earnings is estimated for Tuesday, December 22, 2026, based on past reporting schedules, with a conference call scheduled on Friday, December 18, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

enGene Q3 2026 Earnings FAQ

enGene (NASDAQ:ENGN) reported earnings of -$0.47 per share for Q3 2026, missing the consensus estimate of -$0.4266. The report was announced on Tuesday, September 8, 2026.

enGene's next earnings date is estimated for Tuesday, December 22, 2026. MarketBeat tracks confirmed and estimated earnings dates for enGene on the company's earnings history page.

enGene Earnings Headlines

Unbelievable…Congress is About to Do What?
Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washington is set to take place by November 30th. He believes it could create one of the most chaotic environments in America's history. He predicts those who understand what's happening could do very well over the next 12-18 months, while others may face steep losses. Rickards outlines the five steps he recommends.tc pixel
enGene (NASDAQ:ENGN) Upgraded at Leerink Partners
See More enGene Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like enGene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on enGene and other key companies, straight to your email.

About enGene

enGene (NASDAQ:ENGN) is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA.

View enGene Profile